Controlled trial of cycled antibiotic prophylaxis to prevent initial Pseudomonas aeruginosa infection in children with cystic fibrosis

Thorax

Volumn 65, Issue 10, 2010, Pages 915-920

  Tramper Stranders, Gerdien A ^a   Wolfs, Tom F W ^a   Van Haren Noman, Sanne ^a   Van Aalderen, Wim M C ^b   Nagelkerke, Ad F ^b   Nuijsink, Marianne ^c   Kimpen, Jan L L ^a   Van Der Ent, Cornelis K ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b EMMA CHILDREN S HOSPITAL   (Netherlands)

^c HAGA HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; ANTIBIOTIC AGENT; BETA LACTAM; CIPROFLOXACIN; COLISTIMETHATE; COLISTIN; PLACEBO;

ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DISEASE EXACERBATION; DRUG INDUCED HEADACHE; ERYTHEMA; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INCONTINENCE; INFANT; INFLAMMATION; LUNG FIBROSIS; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; PSEUDOMONAS INFECTION; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SIDE EFFECT; SPUTUM; THORAX RADIOGRAPHY; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 77957195625     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thx.2009.126128     Document Type: Article

References (33)

1. Ratjen F, Doring G. Cystic fibrosis. Lancet 2003;361:681-9.
2. Sadikot RT, Blackwell TS, Christman JW, et al. Pathogen-host interactions in Pseudomonas aeruginosa pneumonia. Am J Respir Crit Care Med 2005;171:1209-23.
3. Nguyen D, Singh PK. Evolving stealth: genetic adaptation of Pseudomonas aeruginosa during cystic fibrosis infections. Proc Natl Acad Sci USA 2006;103:8305-6.
4. Li Z, Kosorok MR, Farrell PM, et al. Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis. JAMA 2005;293:581-8.
5. Emerson J, Rosenfeld M, McNamara S, et al. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol 2002;34:91-100.
6. Kosorok MR, Zeng L, West SE, et al. Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition. Pediatr Pulmonol 2001;32:277-87.
7. Burns JL, Gibson RL, McNamara S, et al. Longitudinal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis. J Infect Dis 2001;183:444-52.
8. Dakin CJ, Numa AH, Wang H, et al. Inflammation, infection, and pulmonary function in infants and young children with cystic fibrosis. Am J Respir Crit Care Med 2002;165:904-10.
9. Douglas TA, Brennan S, Gard S, et al. Acquisition and eradication of P. aeruginosa in young children with cystic fibrosis. Eur Respir J 2009;33:305-11.
10. Sagel SD, Gibson RL, Emerson J, et al. Impact of Pseudomonas and Staphylococcus infection on inflammation and clinical status in young children with cystic fibrosis. J Pediatr 2009;154:183-8.
11. Kozlowska WJ, Bush A, Wade A, et al. Lung function from infancy to the preschool years after clinical diagnosis of cystic fibrosis. Am J Respir Crit Care Med 2008;178:42-9.
12. Valerius NH, Koch C, Hoiby N. Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment. Lancet 1991;338:725-6.
13. Wiesemann HG, Steinkamp G, Ratjen F, et al. Placebo-controlled, double-blind, randomized study of aerosolized tobramycin for early treatment of Pseudomonas aeruginosa colonisation in cystic fibrosis. Pediatr Pulmonol 1998;25:88-92.
14. Ratjen F, Doring G, Nikolaizik WH. Effect of inhaled tobramycin on early Pseudomonas aeruginosa colonisation in patients with cystic fibrosis. Lancet 2001;358:983-4.
15. Gibson RL, Emerson J, McNamara S, et al. Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. Am J Respir Crit Care Med 2003;167:841-9.
16. Gibson RL, Emerson J, Mayer-Hamblett N, et al. Duration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosis. Pediatr Pulmonol 2007;42:610-23.
17. Taccetti G, Campana S, Festini F, et al. Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients. Eur Respir J 2005;26:458-61.
18. Littlewood JM, Miller MG, Ghoneim AT, et al. Nebulised colomycin for early pseudomonas colonisation in cystic fibrosis. Lancet 1985;1:865.
19. Ratjen F. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis. Curr Opin Pulm Med 2006;12:428-32.
20. Jones AM. Eradication therapy for early Pseudomonas aeruginosa infection in CF: many questions still unanswered. Eur Respir J 2005;26:373-5.
21. Heinzl B, Eber E, Oberwaldner B, et al. Effects of inhaled gentamicin prophylaxis on acquisition of Pseudomonas aeruginosa in children with cystic fibrosis: a pilot study. Pediatr Pulmonol 2002;33:32-7. (Pubitemid 34031552)
22. Lebecque P, Leal T, Zylberberg K, et al. Towards zero prevalence of chronic Pseudomonas aeruginosa infection in children with cystic fibrosis. J Cyst Fibros 2006;5:237-44. (Pubitemid 44824859)
23. Bitterle E. Comparison of aerosol delivery efficiency nebulising colistin by electronic and jet nebulisers. 2009. http://ddl-conference.org.uk/files/ posters/44.Tservistas.pdf (accessed 29 Jul 2010).
24. Zapletal A, Samenek TP. Lung function in children and adolescents: methods and reference values. Basel, Munchen: Karger, 1987.
25. Campbell ME, Farmer SW, Speert DP. New selective medium for Pseudomonas aeruginosa with phenanthroline and 9-chloro-9-[4-(diethylamino) phenyl]-9,10-dihydro-10- phenylacridine hydrochloride (C-390). J Clin Microbiol 1988;26:1910-12.
26. Tramper-Stranders GA, van der Ent CK, Slieker MG, et al. Diagnostic value of serological tests against Pseudomonas aeruginosa in a large cystic fibrosis population. Thorax 2006;61:689-93.
27. van der Put JM, Meradji M, Danoesastro D, et al. Chest radiographs in cystic fibrosis. A follow-up study with application of a quantitative system. Pediatr Radiol 1982;12:57-61.
28. van Ewijk BE, Wolfs TF, Fleer A, et al. High Pseudomonas aeruginosa acquisition rate in CF. Thorax 2006;61:641-2. (Pubitemid 44035151)
29. van Ewijk BE, van der Zalm MM, Wolfs TF, et al. Prevalence and impact of respiratory viral infections in young children with cystic fibrosis: prospective cohort study. Pediatrics 2008;122:1171-6.
30. Ratjen F, Walter H, Haug M, et al. Diagnostic value of serum antibodies in early Pseudomonas aeruginosa infection in cystic fibrosis patients. Pediatr Pulmonol 2007;42:249-55.
31. West SE, Zeng L, Lee BL, et al. Respiratory infections with Pseudomonas aeruginosa in children with cystic fibrosis: early detection by serology and assessment of risk factors. JAMA 2002;287:2958-67.
32. Jaques A, Daviskas E, Turton JA, et al. Inhaled mannitol improves lung function in cystic fibrosis. Chest 2008;133:1388-96.
33. Waters V, Ratjen F. Multidrug-resistant organisms in cystic fibrosis: management and infection-control issues. Expert Rev Anti Infect Ther 2006;4:807-19.